Cancer Family
Notochordal Tumor
CI-CAN-00000294Explore in graph →
Non-malignant15 active trials1 evidence items
- NCIt
- C7063
Loading cancer entity…
Cancer Family
CI-CAN-00000294Explore in graph →
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06957327 | A Study of ERAS-601 in People With Chordoma | active not recruiting | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02989636 | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | active not recruiting | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT01407198 | Nilotinib With Radiation for High Risk Chordoma | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04246671 | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | completed | Phase 1 | 37 | Bavarian NordicINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03955042 | Pemetrexed for the Treatment of Chordoma | completed | Phase 1 | 15 | Saint John's Cancer InstituteOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00592748 | Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine | completed | Phase 1 / Phase 2 | 381 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 14, 2026source: clinicaltrials